Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Garber

Showing results (421-430 of 605) with videos related to

Pageof 61
Sort By:
Gynecologic Oncology|September 4, 2012
Impact of genetic testing on endometrial cancer risk-reducing practices in women at risk for Lynch syndromeMatthew B Yurgelun, Rowena Mercado, Margery Rosenblatt, et al.
JCO Clinical Cancer Informatics|March 16, 2026
Interpretable Active Learning for Pedigree Data Deduplication in Cancer GeneticsMaria S Rosito, Aleck E Cervantes, Christine Hong, et al.
Lancet (London, England)|July 9, 2010
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trialAndrew Tutt, Mark Robson, Judy E Garber, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 17, 2005
Ductal lavage of fluid-yielding and non-fluid-yielding ducts in BRCA1 and BRCA2 mutation carriers and other women at high inherited breast cancer riskAllison W Kurian, Meredith A Mills, Margo Jaffee, et al.
JCO Oncology Practice|April 10, 2025
Video Education Is an Acceptable Alternative to Pretest Genetic Counseling for Patients With Breast, Ovarian, Pancreatic, and Metastatic Prostate Cancer: Results From a Randomized StudyKatherine A Schneider, Lauren Massingham, Michelle Weitz, et al.
Journal of Medical Genetics|July 31, 2007
Germline E-cadherin mutations in familial lobular breast cancerS Masciari, N Larsson, J Senz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2002
BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genesDonald A Berry, Edwin S Iversen, Daniel F Gudbjartsson, et al.
JCO Precision Oncology|September 13, 2019
Patients' Medical and Psychosocial Experiences After Detection of a <i>CDH1</i> Variant With Multigene Panel TestingJada G Hamilton, Jessica M Long, Amanda C Brandt, et al.
JCO Precision Oncology|November 22, 2023
Homologous Recombination Deficiency Landscape of Breast Cancers and Real-World Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Patients With Somatic <i>BRCA1</i>/<i>2</i>, Germline <i>PALB2</i>, or Homologous Recombination Deficiency SignatureFelipe Batalini, Russell W Madison, Ethan S Sokol, et al.
The Oncologist|May 20, 2023
Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and ControversiesStefania Morganti, Brittany L Bychkovsky, Philip D Poorvu, et al.
Pageof 61

Showing results (421-430 of 605) with videos related to

Sort By:
Pageof 61
Gynecologic Oncology|September 4, 2012
Impact of genetic testing on endometrial cancer risk-reducing practices in women at risk for Lynch syndromeMatthew B Yurgelun, Rowena Mercado, Margery Rosenblatt, et al.
JCO Clinical Cancer Informatics|March 16, 2026
Interpretable Active Learning for Pedigree Data Deduplication in Cancer GeneticsMaria S Rosito, Aleck E Cervantes, Christine Hong, et al.
Lancet (London, England)|July 9, 2010
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trialAndrew Tutt, Mark Robson, Judy E Garber, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 17, 2005
Ductal lavage of fluid-yielding and non-fluid-yielding ducts in BRCA1 and BRCA2 mutation carriers and other women at high inherited breast cancer riskAllison W Kurian, Meredith A Mills, Margo Jaffee, et al.
JCO Oncology Practice|April 10, 2025
Video Education Is an Acceptable Alternative to Pretest Genetic Counseling for Patients With Breast, Ovarian, Pancreatic, and Metastatic Prostate Cancer: Results From a Randomized StudyKatherine A Schneider, Lauren Massingham, Michelle Weitz, et al.
Journal of Medical Genetics|July 31, 2007
Germline E-cadherin mutations in familial lobular breast cancerS Masciari, N Larsson, J Senz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2002
BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genesDonald A Berry, Edwin S Iversen, Daniel F Gudbjartsson, et al.
JCO Precision Oncology|September 13, 2019
Patients' Medical and Psychosocial Experiences After Detection of a <i>CDH1</i> Variant With Multigene Panel TestingJada G Hamilton, Jessica M Long, Amanda C Brandt, et al.
JCO Precision Oncology|November 22, 2023
Homologous Recombination Deficiency Landscape of Breast Cancers and Real-World Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Patients With Somatic <i>BRCA1</i>/<i>2</i>, Germline <i>PALB2</i>, or Homologous Recombination Deficiency SignatureFelipe Batalini, Russell W Madison, Ethan S Sokol, et al.
The Oncologist|May 20, 2023
Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and ControversiesStefania Morganti, Brittany L Bychkovsky, Philip D Poorvu, et al.
Pageof 61